Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Tecentriq is named as an intervention in 46 current clinical trials in our Germany, Spain, France, Italy, USA, Belgium, South Korea, UK, Australia, Canada, Taiwan, Poland, Netherlands, China, Switzerland, Japan, Israel, Denmark, Portugal, Brazil, Mexico, Austria, Czechia, Turkey, Singapore, Sweden, Norway, India and Egypt registers. 15 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Hoffmann-La Roche (7). The most-studied condition is Hepatocellular Carcinoma.

Trials by status

Recruiting1533%
Active, closed3167%

Trials by phase

Phase 22657%
Phase 3920%
Phase 1613%
Phase 1/237%
Phase 412%
Observational12%

Clinical trials of Tecentriq

46 trials

Study	Phase	Status	Lead sponsor	Registers
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma NCT04803994 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Recruiting	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany, France, Spain, Italy, Austria, Japan
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity NCT04273061 · ClinicalTrials.gov ↗ · Breast Cancer, Lung Cancer, Gastrointestinal Cancer	Phase 2	Recruiting	British Columbia Cancer Agency	Canada
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling NCT04341181 · ClinicalTrials.gov ↗ · Cancer, Tumors, Neoplasms	Phase 2	Recruiting	Ulrik Lassen	Denmark
PLATFORM Study of Precision Medicine for Rare Tumors NCT04423185 · ClinicalTrials.gov ↗ · Rare Tumor	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments NCT05152472 · ClinicalTrials.gov ↗ · Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor	Phase 2	Recruiting	Centre Leon Berard	France
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) NCT05332561 · ClinicalTrials.gov ↗ · Early-stage Breast Cancer	Phase 2	Recruiting	German Cancer Research Center	Germany
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients NCT06003621 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 2	Recruiting	Omico	Australia
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial NCT06342037 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Recruiting	The Netherlands Cancer Institute	Netherlands
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) NCT07153445 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer	Phase 2	Recruiting	Fundación GECP	Spain
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients NCT05703971 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	Genprex, Inc	USA
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant NCT06725121 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Macrovascular Invasion, Liver Transplant Surgery	Phase 1/2	Recruiting	University Health Network, Toronto	Canada
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) NCT04929223 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1	Recruiting	Hoffmann-La Roche	UK, USA, Germany, Spain, Italy, Denmark, Poland, Canada, South Korea, Taiwan, Australia
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC NCT05096715 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma	Phase 1	Recruiting	Massachusetts General Hospital	Israel
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients NCT06012734 · ClinicalTrials.gov ↗ · Metastatic Microsatellite-stable Colorectal Cancer	Phase 1	Recruiting	The Netherlands Cancer Institute	Netherlands
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II NCT05525858 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Solid Tumor, Metastatic Cancer	Observational	Recruiting	Seoul National University Bundang Hospital	South Korea
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma NCT05689671 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Metastatic	Phase 4	Active, closed	Nikolaj Frost MD	Germany
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] NCT02486718 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Japan, South Korea, Taiwan, Australia, Israel
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) NCT03148418 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer NCT03595592 · ClinicalTrials.gov ↗ · Invasive Breast Cancer	Phase 3	Active, closed	Fondazione Michelangelo	Germany, Spain, Italy, Austria
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients NCT03799835 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 3	Active, closed	UNICANCER	France, Spain, Belgium
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC NCT04446117 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer, Prostate Adenocarcinoma	Phase 3	Active, closed	Exelixis	UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy NCT04873362 · Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Portugal, Turkey, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer NCT05091567 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, Germany, Spain, Italy, Belgium, Poland, Turkey, Mexico, South Korea, Taiwan
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) NCT05904886 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612 · ClinicalTrials.gov ↗ · Neoplasm Metastasis	Phase 2	Active, closed	Genentech, Inc	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Czechia, Norway, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness NCT03421288 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany, Switzerland
The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL NCT03463057 · ClinicalTrials.gov ↗ · NHL, DLBCL	Phase 2	Active, closed	Stichting Hemato-Oncologie voor Volwassenen Nederland	Netherlands, Belgium
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer NCT03540420 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	Active, closed	Norwegian University of Science and Technology	Netherlands, Sweden, Denmark, Switzerland, Norway
ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation NCT04082897 · ClinicalTrials.gov ↗ · CLL Transformation	Phase 2	Active, closed	Niguarda Hospital	Italy, Switzerland
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer NCT04186013 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Active, closed	Spanish Oncology Genito-Urinary Group	Spain
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma NCT04356729 · ClinicalTrials.gov ↗ · Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma	Phase 2	Active, closed	F. Stephen Hodi, MD	Israel
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) NCT04563338 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases	Phase 2	Active, closed	University Health Network, Toronto	Canada
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study NCT04589845 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel, Egypt
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC NCT04630730 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 2	Active, closed	Swiss Cancer Institute	Switzerland
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma NCT04722575 · ClinicalTrials.gov ↗ · Melanoma	Phase 2	Active, closed	Fondazione Melanoma Onlus	Italy
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial NCT04727307 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Phase 2	Active, closed	University Hospital, Montpellier	France
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy NCT04962126 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 2	Active, closed	Olivia Newton-John Cancer Research Institute	Australia
Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin NCT05118724 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Active, closed	AIO-Studien-gGmbH	Germany
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements NCT05174650 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy NCT05781308 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Intergroupe Francophone de Cancerologie Thoracique	France
NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing NCT05825625 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Germany
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC NCT05968326 · ClinicalTrials.gov ↗ · Adenocarcinoma, Pancreatic Ductal	Phase 2	Active, closed	Genentech, Inc	UK, USA, Germany, France, Spain, Netherlands, Belgium, Sweden, Canada, South Korea
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab NCT07280377 · ClinicalTrials.gov ↗ · Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic	Phase 1/2	Active, closed	Oncolytics Biotech	Germany
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors NCT03170960 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer	Phase 1	Active, closed	Exelixis	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Australia
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas NCT04808245 · ClinicalTrials.gov ↗ · Newly Diagnosed H3-mutated Glioma	Phase 1	Active, closed	German Cancer Research Center	Germany
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors NCT05581004 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC	Phase 1	Active, closed	Genentech, Inc	USA, Spain, Netherlands, Belgium, Sweden, Canada, South Korea, Taiwan, Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Tecentriq

68 conditions

Hepatocellular Carcinoma4 Bladder Cancer3 Breast Cancer2 Non-Small Cell Lung Cancer2 Cancer2 Melanoma2 Non Small Cell Lung Cancer2 Solid Tumors1 Metastatic Colorectal Cancer1 Urothelial Carcinoma1 Renal Cell Carcinoma1Castration-resistant Prostate Cancer1

All 68 conditions

Condition (as registered)	Trials
Hepatocellular Carcinoma	4
Bladder Cancer	3
Breast Cancer	2
Non-Small Cell Lung Cancer	2
Cancer	2
Melanoma	2
Non Small Cell Lung Cancer	2
Solid Tumors	1
Metastatic Colorectal Cancer	1
Urothelial Carcinoma	1
Renal Cell Carcinoma	1
Castration-resistant Prostate Cancer	1
Neoplasm Metastasis	1
Metastatic Prostate Cancer	1
Prostate Adenocarcinoma	1
Adenocarcinoma, Pancreatic Ductal	1
Small-Cell Lung Cancer	1
Locally Advanced or Metastatic Solid Tumors	1
NSCLC	1
HNSCC	1
Small Cell Lung Cancer Extensive Stage	1
Rare Tumor	1
Newly Diagnosed H3-mutated Glioma	1
Non-small Cell Lung Cancer	1
Early-stage Breast Cancer	1
Non-Small Cell Lung Cancer Metastatic	1
Gastric Cancer	1
Gastroesophageal Junction Adenocarcinoma	1
Intrahepatic Cholangiocarcinoma	1
Invasive Breast Cancer	1
Anal Cancer Metastatic	1
Squamous Cell Carcinoma of the Anus Stage Unspecified	1
Pancreatic Cancer Metastatic	1
Unresectable Pancreatic Carcinoma	1
Colorectal Cancer	1
Unresectable Gastrointestinal Stromal Tumor (GIST)	1
Locally Advanced Gastrointestinal Stromal Tumor (GIST)	1
Metastatic Gastrointestinal Stromal Tumor	1
Stage IIIA Lung Cancer	1
Stage IIIB Lung Cancer	1
CLL Transformation	1
Metastatic Breast Cancer	1
Small-cell Lung Cancer	1
NHL	1
DLBCL	1
Metastatic Microsatellite-stable Colorectal Cancer	1
Tumors	1
Neoplasms	1
Neoplasia	1
Lung Cancer	1
Gastrointestinal Cancer	1
Genitourinary Cancer	1
Hepatocellular Carcinoma (HCC)	1
Macrovascular Invasion	1
Liver Transplant Surgery	1
Downstaging	1
Non-small Cell Lung Cancer Metastatic	1
Liver Metastases	1
Solid Tumor	1
Advanced Solid Tumor	1
Metastatic Cancer	1
Follicular Lymphoma	1
Solid Tumor, Adult	1
Clinical Stage III Cutaneous Melanoma AJCC v8	1
Stage IV Melanoma	1
Unresectable Stage III Cutaneous Melanoma	1
Unresectable Stage IV Cutaneous Melanoma	1
Unresectable Hepatocellular Carcinoma	1

By country register

Register	Trials	Recruiting
Clinical trials in Germany	21	3
Clinical trials in Spain	17	3
Clinical trials in France	14	2
Clinical trials in Italy	14	2
Clinical trials in USA	13	2
Clinical trials in Belgium	13	0
Clinical trials in South Korea	12	2
Clinical trials in UK	11	1
Clinical trials in Australia	11	2
Clinical trials in Canada	11	3
Clinical trials in Taiwan	10	1
Clinical trials in Poland	9	1
Clinical trials in Netherlands	9	2
Clinical trials in China	7	1
Clinical trials in Switzerland	7	0
Clinical trials in Japan	7	1
Clinical trials in Israel	7	1
Clinical trials in Denmark	6	2
Clinical trials in Portugal	6	0
Clinical trials in Brazil	6	0
Clinical trials in Mexico	6	0
Clinical trials in Austria	5	1
Clinical trials in Czechia	4	0
Clinical trials in Turkey	4	0
Clinical trials in Singapore	4	0
Clinical trials in Sweden	4	0
Clinical trials in Norway	2	0
Clinical trials in India	1	0
Clinical trials in Egypt	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Tecentriq trials

How many clinical trials are testing Tecentriq?

46 current trials in our Germany, Spain, France, Italy, USA, Belgium, South Korea, UK, Australia, Canada, Taiwan, Poland, Netherlands, China, Switzerland, Japan, Israel, Denmark, Portugal, Brazil, Mexico, Austria, Czechia, Turkey, Singapore, Sweden, Norway, India and Egypt registers name Tecentriq as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Tecentriq trials recruiting patients?

Yes. 15 of the 46 trials are recruiting: 3 with sites in Germany, 3 with sites in Spain, 2 with sites in France, 2 with sites in Italy, 2 with sites in USA, 2 with sites in South Korea, 1 with sites in UK, 2 with sites in Australia, 3 with sites in Canada, 1 with sites in Taiwan, 1 with sites in Poland, 2 with sites in Netherlands, 1 with sites in China, 1 with sites in Japan, 1 with sites in Israel, 2 with sites in Denmark and 1 with sites in Austria. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Tecentriq clinical trials?

Hoffmann-La Roche (7), Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (4), Genentech, Inc (3) and Exelixis (2), among 31 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tecentriq works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tecentriq works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tecentriq (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Tecentriq clinical trials